Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Loungers FY24 underlying earnings seen ahead of market expectations

(Sharecast News) - Bar and restaurant operator Loungers said on Friday that it had seen continued strong like-for-like sales growth in the 53 weeks ended 21 April and now expects full-year underlying earnings to come in ahead of expectations. Loungers said it had delivered "record total revenue" of £353.5m, up 24.7% on the previous year, reflecting both continuing strong like-for-like sales growth of 7.5% and the "ongoing success" of its new site opening programme.

The AIM-listed group stated the strength of its sales performance had been accompanied by "disciplined management of costs" and a "continued easing of inflationary cost pressures" and, as a result, expects underlying earnings for FY24 to be ahead of market expectations.

Loungers added that its balance sheet "remains strong", with non-property net debt of £9.7m, up from £6.1m a year earlier as a result of the further acceleration of the firm's site roll-out programme during the year, opening a record 36 new sites in FY24.

Chief executive Nick Collins said: "I am delighted with our performance over the year.

"As we start the new financial year we are looking ahead with optimism. Our experience suggests that the UK economy is holding up well and we are well positioned to deliver continued growth."

As of 0935 BST, Loungers shares were up 1.52% at 234.50p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

Hikma boosts injectables business with Xellia assets acquisition
(Sharecast News) - Hikma Pharmaceuticals said on Monday that it has agreed to buy parts of Xellia Pharmaceuticals, a Copenhagen-based specialty company focusing on providing anti-infective treatments and other critical care therapies, for up to $185m.
Ascential on track to hit targets this year
(Sharecast News) - Publishing, events and B2B consultancy group Ascential has said that trading is in line with expectations for the full year, helped by strong growth in marketing and fintech operations.
AstraZeneca's Imfinzi gets US approval for endometrial cancer patients
(Sharecast News) - AstraZeneca said its Imfinzi cancer treatment had been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer.
British Land CFO to join Kingfisher
(Sharecast News) - B&Q owner Kingfisher said it had appointed British Land chief financial officer Bhavesh Mistry to the same role at the home improvement company.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.